Claims for Patent: 8,663,599
✉ Email this page to a colleague
Summary for Patent: 8,663,599
Title: | Pharmaceutical composition of nanoparticles |
Abstract: | The invention discloses a pharmaceutical composition of pH-sensitive liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising a proton-releasing photosensitive compound that releases protons upon photolysis, wherein the compound is in vesicles of the liposomes. A light or UV light is provided to induce the photosensitive compound to release the protons, thus the released protons causing the pH-sensitive liposome to decompose. |
Inventor(s): | Sung; Hsing-Wen (Hsinchu, TW), Liao; Zi-Xian (Hsinchu, TW), Chung; Min-Fan (Hsinchu, TW), Chen; Ko-Jie (Hsinchu, TW), Cheng; Po-Yuan (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA) |
Assignee: | GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW) |
Application Number: | 13/682,929 |
Patent Claims: | 1. A composition of liposomes, comprising a proton-releasing photosensitive compound that releases protons upon photolysis, wherein said compound is loaded in vesicles of
said liposomes that are pH-sensitive.
2. The composition according to claim 1, wherein the liposomes comprises HSPC (L-.alpha.-phosphatidylcholine, hydrogenated), DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), cholesterol, and bicarbonates. 3. The composition according to claim 2, wherein said bicarbonates are sodium bicarbonates, ammonium bicarbonates, potassium bicarbonates, or calcium bicarbonates. 4. The composition according to claim 1, wherein said liposomes are adapted for delivery to a blood vessel or a lymphoid system of an animal subject. 5. The composition according to claim 4, wherein said liposomes enter cells of the animal subject via an endocytosis pathway. 6. The composition according to claim 1, wherein said liposomes further comprise at least one bioactive agent. 7. The composition according to claim 1, wherein said liposomes further comprise a cancer targeting moiety. 8. The composition according to claim 1, wherein said liposomes further comprise a deoxyribonucleic acid. 9. The composition according to claim 1, wherein said liposomes further comprise a small interfering ribonucleic acid. 10. The composition according to claim 1, wherein said liposomes further comprise an anticancer drug. 11. The composition according to claim 1, wherein said liposomes further comprise a chemodrug. 12. The composition according to claim 1, wherein said liposomes further comprise an adjuvant. 13. The composition according to claim 12, wherein said adjuvant is Bacille Calmette-Guerin (BCG), an interferon, or a colony-stimulating factor GM-CSF. 14. The composition according to claim 12, wherein said adjuvant is cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil, intravenous immunoglobulin, or rituximab. 15. The composition according to claim 1, wherein said liposomes further comprise a coagulant. 16. The composition according to claim 1, wherein said liposomes further comprise doxorubicin, camptothecin, paclitaxel, or daunorubicin. 17. The composition according to claim 1, wherein said proton-releasing photosensitive compound is ester o-nitrobenzyl acetate. 18. The composition according to claim 1, wherein the liposomes have a size less than about 300 nanometers. 19. The composition according to claim 1, wherein said liposomes comprise a chemoimmunotherapeutic bioactive agent consisting of an immunologic adjuvant, chemodrugs, and an oxidant. 20. The composition according to claim 1, wherein said liposomes are adapted for delivery to a tumor site directly. |
Details for Patent 8,663,599
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2024-10-05 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2024-10-05 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2024-10-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.